US › Healthcare

4D Molecular Therapeutics Inc (FDMT)

US · Healthcare · Biotechnology

$10.26+1.68%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$3.0M
Revenue YoY
+21664.3%
Net profit
$-68.8M
Profit YoY
-43.3%
EPS
$-1.01
EPS estimate
$-1.00
Net margin
-2,256.6%

EPS came in at -1.01 against a street estimate of -1.00 — a miss of 1.0%.

Key statistics

Market cap
$532.2M
Forward P/E
0.0
P/B
1.18
Book value
$8.64
EPS (TTM)
$-2.57
52-week high
$14.00
52-week low
$5.23
50-day MA
$10.47
200-day MA
$9.77
Beta
2.69

Analyst view

Analysts rate 4D Molecular Therapeutics Inc a buy (9 buy, 2 hold, 1 sell out of 12) with an average price target of $29.10.

Shareholding

Insiders
3.21%
Institutions
101.42%

Largest institutional holders

FundStake
HHG PLC10.04%
RA Capital Management, LLC9.66%
The Goldman Sachs Group Inc8.04%
BlackRock Inc7.93%
Novo A/S6.98%
Bvf Inc5.51%
State Street Corp5.18%
Vanguard Capital Management, LLC4.20%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for 4D Molecular Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.